Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10971	LYN-1604
BP10971	LYN-1604 is a novel activator of ULK1, inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.
BP10928	m-3M3FBS
BP10928	m-3M3FBS is a phospholipase C (PLC) activator.
BP10080	MA242
BP10080	MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).
BP10915	Maackiain
BP10915	1. Maackiain induces apoptosis and growth suppression 2. MAK1 is the second functional gene cloned from Maackiain detoxification.
BP10835	Madecassic acid
BP10835	Madecassic acid is extracted from the whole herb of Centella asiatica.
BP10063	Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD
BP10063	PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM.
BP10503	Marginatoxin
BP10503	Marginatoxin may be a promising chemopreventive agent for treating hepatocellular carcinoma, it induces human hepatoma BEL-7402 cells apoptosis in vitro and in vivo via activation of Fas/FasL-mediated apoptotic pathway.
BP10264	Maritoclax
BP10264	Maritoclax (Marinopyrrole A) is a novel and specific Mcl-1 inhibitor, shows >8 fold selectivity than BCL-xl (IC50 > 80 μM),with an IC50 value of 10.1 μM.
BP10079	Masitinib mesylate
BP10079	Masitinib mesylate is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectively).
BP10702	MAZ51
BP10702	MAZ51 is a VEGFR-3 (Flt-4) tyrosine kinase inhibitor.
BP10969	MBM-55
BP10969	MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
BP10181	MCB-613
BP10181	MCB-613 is an effective steroid receptor coactivator (SRC) stimulator.
BP10941	Mcl1-IN-11
BP10941	Mcl1-IN-11 (Compound G) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.06 and 4.2 μM, respectively.
BP10940	Mcl1-IN-12
BP10940	Mcl1-IN-12 has anti-tumor activity.It is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively.
BP10812	Mcl1-IN-9
BP10812	Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM.
BP10132	Meclizine dihydrochloride
BP10132	Meclizine hydrochloride is a histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.
BP10331	Menin-MLL inhibitor MI-2
BP10331	MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
BP10076	Menthone
BP10076	Menthone has anti-inflammary activity,, it can suppress the lipopolysaccharide (LPS)-induced proinflammatory cytokines, interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha),as well as nuclear factor kappaB (NF-kB).
BP10234	Merestinib
BP10234	LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.
BP10535	Merodantoin
BP10535	Merodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.